The test uses machine learning to analyze biomarkers and clinical features to determine prostate cancer aggressiveness.

The ruling ensures continued coverage, without patient cost-sharing, of services including BRCA testing and colorectal cancer screening, potentially impacting firms like Exact Sciences.

The firm is also considering a US regulatory submission of its QiAcuityDx system along with a companion diagnostic test.

The ASM partnered with the US Centers for Disease Control and Prevention on the guidance published this month in Clinical Microbiology Reviews.

The Helsinki-based firm's test is used to automate breast cancer grading using AI-developed models, and it is integrated into the firm's breast cancer suite.

The company has reduced the turnaround time to a little over 48 hours for its pathogen-agnostic metagenomic next-generation sequencing test service for CNS infections ...

The artificial intelligence-based assay relies on images from an H&E stained biopsy slide and a machine learning model to determine risk of metastasis.

The company plans to bring to market in the coming years a series of microarray-based tests for autoimmune diseases and allergies, among other tests.

The company hopes to complete proof of principle for a companion diagnostic to identify patients with PCa who are likely to need aggressive treatment.

NEW YORK — Sysmex America said on Wednesday that it has received licensing from Health Canada for its CN-3000 and CN-6000 automated blood coagulation analyzers. The CN-3000 and CN-6000 are designed ...